TY - JOUR
T1 - Basic and clinical studies on cefluprenam in urinary tract infections
AU - Sakuramoto, Koushi
AU - Fujita, Ryuji
AU - Watanabe, Toyohiko
AU - Takenaka, Tadasu
AU - Monden, Kouichi
AU - Hayashi, Toshihide
AU - Hata, Kazuhiro
AU - Ono, Noriaki
AU - Nasu, Yoshitsugu
AU - Tsugawa, Masaya
AU - Kumon, Hiromi
AU - Ohmori, Hiroyuki
AU - Nanba, Katsuichi
AU - Katayama, Yasuhiro
AU - Akaeda, Teruaki
PY - 1995/1/1
Y1 - 1995/1/1
N2 - We studied the antibacterial activity and clinical efficacy of cefluprenam (CFLP), a new injectable cephalosporin antibiotic, in urinary tract infections. 1) Antibacterial activity: The MICs of CFLP were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ceftazidime (CAZ), cefoperazone (CPZ), latamoxef (LMOX) and imipenem (IPM). In general, the antibacterial activity of CFLP was superior to those of other compared cephems except for IPM, but slightly inferior to that of IPM. 2) Clinical efficacy: Fourteen patients with complicated urinary tract infection were treated once or twice a day with 0.5g or 1.0g of CFLP. Out of 14, 12 cases were evaluated according to the criteria of the apanese UTI Committee. The overall clinical efficacy rate was 66.7%(8/12). Bacteriologically, 17 of 20 strains (85%) were eradicated. 3) Side effect: No clinical side effects and no abnormal laboratory changes were observed in any cases.
AB - We studied the antibacterial activity and clinical efficacy of cefluprenam (CFLP), a new injectable cephalosporin antibiotic, in urinary tract infections. 1) Antibacterial activity: The MICs of CFLP were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ceftazidime (CAZ), cefoperazone (CPZ), latamoxef (LMOX) and imipenem (IPM). In general, the antibacterial activity of CFLP was superior to those of other compared cephems except for IPM, but slightly inferior to that of IPM. 2) Clinical efficacy: Fourteen patients with complicated urinary tract infection were treated once or twice a day with 0.5g or 1.0g of CFLP. Out of 14, 12 cases were evaluated according to the criteria of the apanese UTI Committee. The overall clinical efficacy rate was 66.7%(8/12). Bacteriologically, 17 of 20 strains (85%) were eradicated. 3) Side effect: No clinical side effects and no abnormal laboratory changes were observed in any cases.
KW - cefluprenam
UR - http://www.scopus.com/inward/record.url?scp=0029617589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029617589&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1995.43.Supplement4_127
DO - 10.11250/chemotherapy1995.43.Supplement4_127
M3 - Article
AN - SCOPUS:0029617589
SN - 1340-7007
VL - 43
SP - 127
EP - 133
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
ER -